Qing Shi
Houston Methodist Hospital
3 Papers
Qing Shi is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Medicine & Gene silencing. The author has an hindex of 1, co-authored 2 publications. Previous affiliations of Qing Shi include Baylor College of Medicine.
Chat about Author
Papers
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Na Zhao,Jin Cao,Longyong Xu,Qianzi Tang,Lacey E. Dobrolecki,Xiangdong Lv,Manisha Talukdar,Yang Lu,Xiaoran Wang,Dorothy Hu,Qing Shi,Yu Xiang,Yunfei Wang,Xia Liu,Wen Bu,Yi Jiang,Mingzhou Li,Yingyun Gong,Zheng Sun,Haoqiang Ying,Bo Yuan,Xia Lin,Xin-Hua Feng,Xin-Hua Feng,Sean M. Hartig,Feng Li,Haifa Shen,Yiwen Chen,Leng Han,Qingping Zeng,John B. Patterson,Benny Abraham Kaipparettu,Nagireddy Putluri,Frank Sicheri,Jeffrey M. Rosen,Michael T. Lewis,Xi Chen +36 more
TL;DR: It is shown that oncogenic MYC regulates the inositol-requiring enzyme 1/X-box binding protein 1 (XBP1) branch of the UPR in breast cancer via multiple mechanisms, and it is demonstrated that XBP1 is a synthetic lethal partner of MYC.
A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine
Awadalkareem Adam,Qing Shi,Binbin Wang,Jing Zou,Junhua Mai,Samantha R. Osman,Wenzhe Wu,Xuping Xie,Patricia V. Aguilar,Xiaoyong Bao,Pei Yong Shi,Haifa Shen,Tian Wang +12 more
TL;DR: In this article , a modified porous silicon microparticle (mPSM) adjuvant to SARS-CoV-2 receptor-binding domain (RBD) vaccine activated dendritic cells and generated more potent and durable systemic humoral and type 1 helper T (Th) mediated immune responses than alum-formulated RBD following parenteral vaccination.
7
Virus-Mimic mRNA Vaccine for Cancer Treatment
Chaoyang Meng,Chaoyang Meng,Zhe Chen,Zhe Chen,Junhua Mai,Qing Shi,Shaohui Tian,Shaohui Tian,Louis Hinkle,Jun Li,Jun Li,Zhe Zhang,Maricela R. Ramirez,Licheng Zhang,Yitian Xu,Jilu Zhang,Ping Ying Pan,Ping Ying Pan,Shu Hsia Chen,Shu Hsia Chen,Hangwen Li,Haifa Shen,Haifa Shen +22 more
- 17 Sep 2021
TL;DR: A mRNA virus‐mimicking vaccine platform that is comprised of a phospholipid bilayer encapsulated with a protein‐nucleotide core consisting of antigen‐encoding mRNA molecules, unmethylated CpG oligonucleotides and positively charged proteins is described.